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Protocol
AbstrACt
Objectives Covert stroke after non-cardiac surgery may 
have substantial impact on duration and quality of life. 
In non-surgical patients, covert stroke is more common 
than overt stroke and is associated with an increased risk 
of cognitive decline and dementia. Little is known about 
covert stroke after non-cardiac surgery. NeuroVISION is 
a multicentre, international, prospective cohort study that 
will characterise the association between perioperative 
acute covert stroke and postoperative cognitive function.
setting and participants We are recruiting study 
participants from 12 tertiary care hospitals in 10 countries 
on 5 continents.
Participants We are enrolling patients ≥65 years of age, 
requiring hospital admission after non-cardiac surgery, 
who have an anticipated length of hospital stay of at least 
2 days after elective non-cardiac surgery that occurs under 
general or neuraxial anaesthesia.
Primary and secondary outcome measures Patients 
are recruited before elective non-cardiac surgery, and 
their cognitive function is measured using the Montreal 
Cognitive Assessment (MoCA) instrument. After surgery, 
a brain MRI study is performed between postoperative 
days 2 and 9 to determine the presence of acute brain 
infarction. One year after surgery, the MoCA is used 
to assess postoperative cognitive function. Physicians 
and patients are blinded to the MRI study results until 
after the last patient follow-up visit to reduce outcome 
ascertainment bias. We will undertake a multivariable 
logistic regression analysis in which the dependent 
variable is the change in cognitive function 1 year 
after surgery, and the independent variables are acute 
perioperative covert stroke as well as other clinical 
variables that are associated with cognitive dysfunction.
Conclusions The NeuroVISION study will characterise 
the epidemiology of covert stroke and its clinical 
consequences. This will be the largest and the most 
comprehensive study of perioperative stroke after non-
cardiac surgery.
trial registration number NCT01980511; Pre-results.
IntrOduCtIOn   
Worldwide, 200 million adults have non-car-
diac surgery requiring hospital admission 
annually.1 Non-cardiac surgery provides 
strengths and limitations of this study
 ► A blinded study design in order to minimise bias in 
characterising the impact of postoperative covert 
stroke on cognitive function.
 ► A method of evidence-informed data imputation to 
minimise systematic bias from incomplete cognitive 
assessments.
 ► The Montreal Cognitive Assessment instrument 
used to measure cognitive function is clinically rele-
vant and assesses multiple cognitive domains.
 ► Cognitive testing instruments may be insensitive to 
subtle changes in cognitive function.
 ► Availability of MRI scanners precluded the enrolment 
of all eligible patients.
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substantial benefit to most patients; however, it is associ-
ated with major vascular complications including myocar-
dial infarction, cardiac arrest, stroke and death. Although 
only a small proportion of patients will suffer a clinically 
overt perioperative stroke (~0.5%), these events often 
have a devastating effect on patients’ quality and duration 
of life.2 It is likely that there are many more covert than 
overt strokes, but the incidence of covert brain infarcts 
after non-cardiac surgery, and their implications for 
patients and families remain unknown.
Perioperative overt stroke
The true incidence of overt stroke after non-cardiac 
surgery remains unknown, and the estimates of the risk of 
stroke in the current literature vary from 0.2% to 4.3%.3–5 
Stroke and postoperative cognitive dysfunction are of the 
utmost concern to patients. A study of 1216 patients iden-
tified common fears when facing elective knee surgery, 
and found that the largest proportion of participants were 
‘very concerned’ about perioperative ‘brain damage’ 
(19%, 234/1216), followed by ‘memory loss’ (17%, 
210/1216).6 In contrast, only 12% (147/1216) were very 
concerned about death in the perioperative period.
In the Perioperative Ischemic Evaluation (POISE) 
Trial (international randomised trial of 8351 patients 
from 190 centres in 23 countries),2 stroke carried a high 
degree of morbidity and mortality. Among the 0.7% of 
patients who suffered a stroke, 32% died within 30 days 
and, of the survivors, 58% were left with major disability. 
In comparison, a meta-analysis of patient-level data from 
1384 participants allocated to the placebo group of six 
major randomised controlled trials conducted outside 
of the perioperative setting demonstrated substan-
tially lower mortality (13% died within 3 months) and 
morbidity (28% suffered a major disability). Moreover, 
these non-operative studies excluded patients with minor 
strokes.7
The high incidence of death and disability after periop-
erative stroke compared with stroke in the ambulatory 
setting suggest the possibility that we may be missing 
some strokes with mild or moderate severity after surgery, 
and these covert events may be prognostically important.
Perioperative covert brain infarction
Covert stroke is an acute ischaemic event that has no 
apparent clinical manifestations, but may increase the 
risk of cognitive and physical decline.8 9 Modern neuro-
imaging techniques (MRI sequences) can detect acute 
covert stroke with a high degree of accuracy.10 Several 
large studies have evaluated the prevalence of covert 
stroke in the general population of older adults, but only 
a few small studies have evaluated the frequency of covert 
stroke in the perioperative setting after cardiac and 
carotid artery surgery, but not after non-cardiac surgery.
No study has examined the association of covert stroke 
with cognitive decline after surgery. In the non-surgical 
population, evidence suggests covert stroke is associ-
ated with, and may be causally related to, dementia and 
cognitive decline,11 as well as impairments in activities of 
daily living.12
ObjeCtIves Of the neurOvIsIOn study
The NeuroVISION study aims to characterise the inci-
dence, impact and risk factors of covert stroke in adults 
undergoing non-cardiac surgery. We will do this using a 
postoperative MRI study of the brain completed 2–9 days 
after surgery and follow-up assessment of neurocognitive 
function.
Primary outcome
The primary outcome is postoperative cognitive dysfunc-
tion, defined as a decrease of two or more points on 
the Montreal Cognitive Assessment (MoCA) scale from 
preoperative baseline to 1-year follow-up. We hypoth-
esise that perioperative covert stroke is associated with 
cognitive dysfunction 1 year after surgery. We believe that 
cognitive assessment at 1 year after surgery informs the 
long-term impact of covert stroke, while cognitive assess-
ments performed sooner after surgery may be affected by 
postoperative changes (eg, incisional pain, analgesics and 
surgery-related functional limitations).
The National Institute of Neurological Disorders and 
Stroke (NINDS) has coined the term ‘vascular cognitive 
impairment’ (VCI) for neurological dysfunction that is 
caused by, or associated with vascular factors.13 They have 
recommended the MoCA instrument as a tool for neuro-
cognitive testing of patients with suspected VCI,13 and 
MoCA has shown good correlation when compared with 
the full 60 min NINDS VCI Battery neuropsychological 
assessment.14
MoCA is used extensively in the assessment of 
cognitive function after stroke and cerebrovascular 
disease.14–18 It is superior to the Mini-Mental State Exam-
ination (MMSE) in assessments of language skills, visu-
al-spatial and executive function, and in the diagnosis 
of cognitive dysfunction after stroke.15 17 MoCA assesses 
multiple cognitive domains, and it provides a thorough 
assessment of the impact of perioperative covert brain 
infarction. The MoCA instrument is more sensitive than 
the MMSE, and has a minimal ceiling effect.19 We will 
exclude patients with a history of dementia, thereby 
minimising the risk of floor effect with respect to the 
change in cognitive score.
Cognitive decline due to the ageing process is asso-
ciated with lower MoCA scores. Previous studies have 
shown a decline of 1.4 –2.2 points on the MoCA score 
for every additional 10 years of age in patients 65 years of 
age and older20 21 It can be interpreted that a two-point 
difference in the MoCA score represents 10 years of brain 
ageing, and this would be relevant to patients and their 
caregivers. A change of two points on the MoCA score has 
been used as a cut-off for significant cognitive decline in 
published studies.22
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MethOds
study design
The NeuroVISION Study is a multicentre, prospective 
cohort study being conducted in 12 tertiary hospitals 
from 10 countries on 5 continents.
study population
We are enrolling patients ≥65 years of age, requiring 
hospital admission after non-cardiac surgery, and have an 
anticipated length of hospital stay of at least 2 days after 
elective non-cardiac surgery that occurs under general or 
neuraxial anaesthesia. We obtain consent for participa-
tion in NeuroVISION from the patients before surgery.
Patients who have a contraindication to MRI scanning 
(eg, implanted devices not safe for MRI studies, claustro-
phobia), patients who are unable or unwilling to attend 
the follow-up appointments, patients who have a docu-
mented history of dementia as diagnosed by a physician 
or who reside in a nursing home, and patients under-
going carotid artery surgery or intracranial surgery are 
excluded from the study. We are also excluding patients 
who are not able to complete neurocognitive testing due 
to language, vision or hearing impairment, those who are 
not able to communicate with the research staff due to 
language barriers, patients who do not consent to partic-
ipate, and those who were previously enrolled in the 
NeuroVISION Study.
Patient and public involvement
Patients and public were not involved in the development 
of the research question or the design of the study. Study 
results will be disseminated by publication in a medical 
journal, and poster presentation at a medical conference.
sampling strategy
In the NeuroVISION Pilot Study,23 there were approxi-
mately 15–30 eligible patients per centre each week, but 
due to limitations on the availability of the MRI scanners, 
each centre could only recruit up to two patients per 
week. Because of the disparity between the number of 
eligible patients and the MRI capacity, we are employing 
a sampling strategy to ensure proportionate representa-
tion of patients that reflects the overall surgical popula-
tion by randomly assigning the days of recruitment for 
specific surgery subtypes, proportional to the prevalence 
of surgery type at each local centre.
Clinical data collection
Research personnel approach all patients who fulfil the 
eligibility criteria to obtain informed consent before the 
day of surgery. After obtaining written informed consent 
from eligible patients or their legal decision-makers, 
research personnel administer the MoCA question-
naire, the Digit-Symbol Substitution Test (DSST)24 
and the Trail-Making Test Part B (TMT-B)25 to assess 
baseline cognitive function. They also administer the 
Lawton Instrumental Activities of Daily Living (iADL) 
Scale,26 modified Rankin Scale,27 Geriatric Depression 
Scale (GDS)28 and the EQ-5D questionnaire29 to assess 
physical function, mood and health-related quality of life 
at baseline. The research personnel interview patients 
and review their charts to obtain baseline clinical infor-
mation including patient demographics (age, sex and 
ethnicity), medical history (eg, prior cerebrovascular 
disease, other vascular risk factors and adverse cardiac 
events, venous thromboembolic disease, depression and 
anxiety, and respiratory diseases) and medication use 
prior to surgery (eg, cardiac medications, antiplatelet 
agents and anticoagulants, narcotics and other psycho-
active medications).
Research personnel follow patients until hospital 
discharge. The patients are screened for delirium two 
times per day during the first 72 hours after surgery. 
Assessment for delirium is performed using the confu-
sion assessment method.30 Study personnel also collect 
detailed haemodynamic data as well as predefined clin-
ical outcomes (overt stroke or transient ischaemic attack 
(TIA), adverse vascular events, bleeding, infection and 
kidney injury) occurring during the hospital stay.
Research personnel contact patients by phone 30 days 
after surgery. They collect data regarding predefined clin-
ical outcomes (overt stroke or TIA, adverse vascular events, 
bleeding, infection and kidney injury), and administer 
the Lawton iADL Scale, Modified Rankin Scale, GDS and 
EQ-5D questionnaires. At 1 year after surgery, research 
personnel assess the patients in person. They collect data 
regarding predefined clinical outcomes (overt stroke or 
TIA, adverse vascular events, incident dementia, incident 
depression or anxiety), and administer the MoCA, DSST, 
TMT, Lawton iADL Scale, Modified Rankin Scale, GDS 
and EQ-5D questionnaires.
detection of acute stroke in the perioperative setting
Acute postoperative covert stroke is detected using an 
MRI study of the brain performed between postoperative 
days 2 and 9, as early as the patient can tolerate the proce-
dure. The majority of the covert strokes occurred by post-
operative day 2 in previous large perioperative trials,2 31 
and we have chosen the timing of MRI on the basis of this 
experience, as well as the similarity to prior protocols.32–34
The MRI sequences consist of axial fluid-attenuated 
inversion recover (FLAIR), gradient echo (GRE), T2 
and diffusion-weighted imaging (DWI) with apparent 
diffusion coefficient (ADC) mapping. MRI sequences are 
performed according to the local standard of care with 
a minimum 1.5 T MRI machine, and a slice thickness of 
3–5 mm, with no gap. The DWI sequence has the ability 
to detect acute cerebral ischaemia that has occurred 
during the time window of minutes before the study up to 
approximately 10 days prior.35 Therefore, it is not neces-
sary to obtain a preoperative MRI scan in order to detect 
new covert brain infarctions. DWI MRI is very sensitive 
for the diagnosis of cerebral ischaemia, approaching 
100%.10 35 Where relevant, we use the ADC maps to aid 
us in determining whether a DWI lesion is new or old: 
a component of the DWI signal comes from T2 prolon-
gation, and discriminating new from chronic lesions is 
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routinely done by assessing the ADC map for evidence of 
restricted diffusion.
Patient identifiers are removed, and MRI images are 
electronically transferred via a secure encrypted connec-
tion to the central imaging core laboratory. Two sepa-
rate teams of clinicians with expertise in neuroradiology 
independently assess the studies in duplicate and provide 
a consensus interpretation regarding the presence of 
imaging lesions that represent acute perioperative cere-
bral ischaemia and chronic ischaemic findings, haem-
orrhages and white matter hyperintensities, defined 
according to consensus criteria.36 Any disagreements are 
resolved by consensus. These clinicians are blinded to the 
baseline characteristics and clinical outcomes.
ethics and blinding of the MrI study results
The results of the MRI scans are blinded until after the 
last patient follow-up visit. However, the MRI scans are 
reviewed immediately after image acquisition for clini-
cally relevant non-ischaemic incidental findings. If iden-
tified, these findings are immediately reported to the 
study team and the attending physician involved in the 
care of the patient, and recorded in the study database. 
This protocol is in keeping with the Canadian Tri-Council 
policy defined in ‘Ethical Conduct for Research Involving 
Humans’,37 as well as previously published literature.38 
The research ethics board at each site approved the 
protocol prior to patient recruitment.
We blind healthcare providers and patients to the MRI 
results for the following reasons: (1) blinding of study 
results eliminates potential bias in the ascertainment of 
study outcomes; (2) this study is not a part of the stan-
dard of care in the postoperative period; (3) the impli-
cations of acute covert stroke in the perioperative period 
are unknown and any management decisions on the basis 
of the MRI study would not be based on evidence but 
could positively or negatively impact outcomes; (4) any 
incidental finding, such as a tumour, is communicated 
to the attending physicians, as soon as the scan is read 
and (5) the research MRI study will be available for future 
comparisons if required for clinical care after the comple-
tion of the study.
sample size
Our sample size calculation was based on our primary 
objective, the proportion of patients with a decrease of 
two or more points on the MoCA scale from preoperative 
baseline to 1-year follow-up. We will undertake a multivari-
able analysis to determine if postoperative covert stroke 
is associated with the incidence of postoperative cogni-
tive dysfunction as measured by the MoCA, at 1 year after 
surgery (ie, the dependent variable). The International 
Study of Postoperative Cognitive Dysfunction 1 of post-
operative cognitive dysfunction in patients aged 60 years 
or older39 demonstrated a 9.9% incidence of postopera-
tive cognitive dysfunction 3 months after surgery (95% CI 
8.1% to 12.0%), while a subsequent study40 showed an 
incidence of 12.7% in patients over the age of 60 (95% CI 
8.9% to 16.4%). Increasing age was associated with an 
increased risk of cognitive dysfunction (5.7% in patients 
under 60 vs 12.7% in patients 60 years or older, p<0.001). 
Our study recruits patients who are at least 65 years old, 
and the risk of cognitive dysfunction may be even greater 
in this group. From non-operative literature, we expect 
that covert stroke will be associated with at least a twofold 
increase in the risk of cognitive dysfunction.11 41
A sample size of 900 patients would allow us to detect a 
minimum OR of 1.89 for the risk of cognitive dysfunction 
after a covert perioperative stroke, with 80% power and 
a two-sided alpha of 0.05, assuming a 30% incidence of 
postoperative cognitive dysfunction and a 10% incidence 
of postoperative covert brain infarction. A sample size of 
1000 patients would allow us to detect a minimum OR of 
1.93 for the risk of cognitive dysfunction after a covert 
perioperative stroke, with 80% power and a two-sided 
alpha of 0.05, assuming a 20% incidence of postoperative 
cognitive dysfunction and a 10% incidence of postopera-
tive covert brain infarction. A sample size of 1100 patients 
would allow us to detect a minimum OR of 2.17 assuming 
a 10% incidence of postoperative cognitive dysfunction 
and a 10% incidence of covert stroke, and would allow 
us to detect a minimum OR of 2.18 assuming a 30% inci-
dence of postoperative cognitive dysfunction and a 5% 
incidence of covert stroke (see table 1).
Analysis plan for primary objective
Our primary objective is to characterise the impact of 
postoperative covert stroke on neurocognitive function 
1 year after elective non-cardiac surgery. We will under-
take a multivariable logistic regression analysis to develop 
a model in which the dependent variable is a decrease in 
the MoCA score of ≥2, 1 year after surgery compared with 
the baseline measurement. The independent variables 
Table 1 Minimum detectable ORs at a power of 80% and alpha of 0.05 for a given sample size, according to incidence of 
cognitive dysfunction and covert stroke
Incidence of 
covert stroke
Incidence of postoperative cognitive dysfunction
10% 20% 30%
Sample size (no of patients) Sample size (no of patients) Sample size (no of patients) 
900 1000 1100 900 1000 1100 900 1000 1100
5% 2.96 2.83 2.72 2.49 2.39 2.31 2.36 2.26 2.18
10% 2.32 2.24 2.17 1.99 1.93 1.88 1.89 1.83 1.78
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are acute covert stroke in the perioperative setting (we 
will exclude patients who suffer an acute clinically symp-
tomatic stroke in the time period between surgery and the 
MRI study, but expect this event to be very infrequent); 
history of stroke, coronary artery disease or peripheral 
vascular disease; depression; age; sex; baseline neurocog-
nitive function as measured by MoCA; baseline physical 
impairment as measured by the Lawton scale; discontinu-
ation of opioid or benzodiazepine medication; initiation 
of cholinesterase inhibitor and surgery type.
For all regression models, we will report the ORs, 95% 
CIs and associated p values. For all tests, we will use a 
two-sided alpha <0.05 level of significance. Examination 
of residuals will provide an assessment of model assump-
tions for regression analyses. Goodness of fit for the 
models will be assessed using appropriate Hosmer-Leme-
show tests. For multivariable regression analysis, we will 
assess for multicollinearity (correlations among predictor 
variables)42 using the variance inflation factor (VIF), 
which measures the extent to which the variance of the 
model coefficients is inflated (because of the correlation 
of the variable with other predictor variables) if that vari-
able is included in the model. We will consider variables 
with VIF >10 collinear, and if this occurs, we will exclude 
one of the collinear variables from the analysis.
Approach to missing data
Even small proportions of missing data can bias study 
results, and cognitive decline may increase the risk of loss 
to follow-up and the risk of incomplete cognitive assess-
ment. This may introduce systematic bias in the study anal-
ysis. It is possible to counteract this bias if the reason for 
missing data is known.43 44 We are collecting the reasons 
for missing data, and will use a method of evidence-in-
formed data imputation to minimise systematic bias from 
incomplete cognitive assessments (see table 2).
COnClusIOn
Non-cardiac surgery is common, but despite evidence 
that perioperative brain damage and cognitive dysfunc-
tion is a major concern to patients undergoing elective 
surgery, there are limited data regarding the epidemi-
ology of cerebral ischaemia during this period. If the 
non-cardiac surgery setting is similar to the non-oper-
ative and cardiac surgery evidence regarding covert 
stroke, upwards of 10 million adults worldwide may suffer 
perioperative covert brain infarctions. The NeuroVISION 
study will characterise the epidemiology of covert stroke 
and its clinical consequences. This is the largest study of 
perioperative covert stroke after non-cardiac surgery and 
will provide important insights for the millions of elderly 
adults undergoing non-cardiac surgery annually.
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Table 2 Evidence-informed data imputation of missing data for cognitive assessments
Probability of 
cognitive decline Reported reasons for missing Data imputation
Missing data 
classification
Confirmed New diagnosis of dementia Multiple imputations centred at the 
average MoCA score change for patients 
with new diagnosis of dementia, mild 
cognitive impairment or those started on 
medication to treat cognitive impairment.
Informative 
missingNew diagnosis of mild cognitive impairment
Started a medication to treat cognitive 
impairment (acetyl cholinesterase inhibitor, 
NMDA-receptor antagonist)
Probable New diagnosis of stroke Multiple imputations centred at the 
average MoCA score change for those 
with MRI finding of old stroke or old 
cerebral small vessel disease
Cardiovascular death
Impairment on other related scale: decreased 
iADL (Lawton), depression (GDS)
Admission to long-term care facility or similar 
institution
Significant cognitive impairment reported by 
family or caregiver
Unlikely Refusal or missed, but reported well Multiple imputations centred at zero 
change in MoCA value
Unknown Lost to follow-up (likely <1%) Imputed directly through mixed model Missing at 
random
GDS, Geriatric Depression Scale; iADL, Lawton Instrumental Activities of Daily Living; MoCA, Montreal Cognitive Assessment; NMDA, 
N-methyl-D-aspartate. 
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